Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30388095 | 1.00 | KDM4E (0.58) | KDM4EKMT2AUSP2PTGS2ATM | |
| SCHEMBL5928786 | 0.83 | KDM4E (0.63) | KDM4EKMT2AUSP2PTGS2ATM | |
| SCHEMBL16416583 | 0.79 | NPC1 (0.54) | KDM4EKMT2APTGS2ALDH1A1NPC1 | |
| SCHEMBL3709037 | 0.76 | NPC1 (0.59) | KDM4EKMT2AUSP2PTGS2ATM | |
| SCHEMBL1663643 | 0.75 | NOS2 (0.55) | KDM4EKMT2AALDH1A1NPC1HPGD | |
| SCHEMBL1302793 | 0.75 | KDM4E (0.66) | KDM4EKMT2AUSP2PTGS2ATM | |
| SCHEMBL1428216 | 0.74 | KDM4E (1.00) | KDM4EKMT2AUSP2ATMALDH1A1 | |
| SCHEMBL30883267 | 0.74 | KDM4E (1.00) | KDM4EKMT2AUSP2ATMALDH1A1 | |
| SCHEMBL15362026 | 0.74 | KDM4E (0.64) | KDM4EKMT2AUSP2PTGS2ATM | |
| SCHEMBL4140794 | 0.73 | SMN1; SMN2 (0.60) | KDM4EKMT2APTGS2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609674-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012067824-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122890-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122890-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNQ3 | KDM4E 854/4885KMT2A 432/4885USP2 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.